TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0

TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On August8, 2017, TESARO,Inc. (the “Company”) issued a press release announcing its operating results for the quarter ended June30, 2017. A copy of the press release is attached to this current report as Exhibit99.1 and is incorporated herein by reference. TESARO,Inc. has scheduled a conference call and webcast for 4:15 p.m.Eastern time on August8, 2017 to discuss its operating results for the quarter ended June30, 2017 and provide an update on the Company’s commercial products and development programs.

The information contained in this report, including Exhibit99.1, is being furnished to the Securities and Exchange Commission and shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that section. Furthermore, such information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Section9 — Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo.

Description

99.1

TESARO,Inc. press release dated August8, 2017 announcing operating results for the quarter ended June30, 2017.


TESARO, Inc. Exhibit
EX-99.1 2 a17-19099_1ex99d1.htm EX-99.1 Exhibit 99.1     TESARO ANNOUNCES SECOND-QUARTER 2017 OPERATING RESULTS   ·                  ZEJULA is the most prescribed PARP inhibitor in U.S.; Q2 net sales totaled $26 million in first quarter of availability   ·                  Recently opened European niraparib EAP has enrolled 200 patients   ·                  VARUBY oral launch now underway in Europe   ·                  Dose-escalation of TSR-022 (anti-TIM-3) completed and combination trial with TSR-042 (anti-PD-1) initiated   ·                  Regulatory strategy defined with FDA for TSR-042 in MSI-high cancers and registration study ongoing   ·                  License agreement signed with Takeda in July for niraparib development and commercialization in Japan and certain other countries with a $100 million upfront payment and up to $240 million in milestones   WALTHAM,…
To view the full exhibit click here

About TESARO,Inc. (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.